These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 25556322)
1. Correlation between SPARC (Osteonectin) expression with immunophenotypical and invasion characteristics of pituitary adenomas. Onoz M; Basaran R; Gucluer B; Isik N; Kaner T; Sav A; Elmaci I APMIS; 2015 Mar; 123(3):199-204. PubMed ID: 25556322 [TBL] [Abstract][Full Text] [Related]
2. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332 [TBL] [Abstract][Full Text] [Related]
3. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397 [TBL] [Abstract][Full Text] [Related]
8. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas. Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500 [TBL] [Abstract][Full Text] [Related]
9. CD147 expression in pituitary adenomas and its significance for clinical outcome. Qu X; Yang W; Jiang M; Han T; Han L; Qu Y; Wang G; Shi D; Xu G Hum Pathol; 2010 Aug; 41(8):1165-71. PubMed ID: 20381119 [TBL] [Abstract][Full Text] [Related]
10. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370 [TBL] [Abstract][Full Text] [Related]
11. A classification tree approach for pituitary adenomas. Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019 [TBL] [Abstract][Full Text] [Related]
12. Biologic markers of invasive pituitary adenomas involving the sphenoid sinus. Gandour-Edwards R; Kapadia SB; Janecka IP; Martinez AJ; Barnes L Mod Pathol; 1995 Feb; 8(2):160-4. PubMed ID: 7777477 [TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas. Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918 [TBL] [Abstract][Full Text] [Related]
14. Determination of Ki-67 labeling index in pituitary adenomas using MIB-1 monoclonal antibody. Lath R; Chacko G; Chandy MJ Neurol India; 2001 Jun; 49(2):144-7. PubMed ID: 11447433 [TBL] [Abstract][Full Text] [Related]
15. Expression of Ki-67, p53 and vascular endothelial growth factor (VEGF) concomitantly in growth hormone-secreting pituitary adenomas; which one has a role in tumor behavior ? Yarman S; Kurtulmus N; Canbolat A; Bayindir C; Bilgic B; Ince N Neuro Endocrinol Lett; 2010; 31(6):823-8. PubMed ID: 21196926 [TBL] [Abstract][Full Text] [Related]
16. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249 [TBL] [Abstract][Full Text] [Related]
17. [Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas]. Miyagami M; Nakamura S No To Shinkei; 1998 Jan; 50(1):27-32. PubMed ID: 9493195 [TBL] [Abstract][Full Text] [Related]
18. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Gejman R; Swearingen B; Hedley-Whyte ET Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942 [TBL] [Abstract][Full Text] [Related]
19. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Fenouille N; Robert G; Tichet M; Puissant A; Dufies M; Rocchi S; Ortonne JP; Deckert M; Ballotti R; Tartare-Deckert S Pigment Cell Melanoma Res; 2011 Feb; 24(1):219-32. PubMed ID: 20955243 [TBL] [Abstract][Full Text] [Related]
20. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas. Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]